Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Public ClinicalTrials.gov record NCT01902173. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I/II trial studies the side effects and the best dose of uprosertib when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IIIC-IV cancer. Uprosertib, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving uprosertib with dabrafenib and trametinib may be a better treatment for cancer.
Study identification
- NCT ID
- NCT01902173
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 27 participants
Conditions and interventions
Conditions
- Hematopoietic and Lymphoid Cell Neoplasm
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced Melanoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Melanoma
- Stage IIIC Cutaneous Melanoma AJCC v7
- Stage IV Cutaneous Melanoma AJCC v6 and v7
- Unresectable Malignant Solid Neoplasm
- Unresectable Melanoma
Interventions
- Biopsy Procedure
- Biospecimen Collection Procedure
- Computed Tomography Procedure
- Dabrafenib Mesylate Drug
- Magnetic Resonance Imaging Procedure
- Trametinib Dimethyl Sulfoxide Drug
- Uprosertib Drug
Procedure · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 7, 2013
- Primary completion
- May 15, 2018
- Completion
- Dec 22, 2023
- Last update posted
- Jan 13, 2025
2013 – 2023
United States locations
- U.S. sites
- 16
- U.S. states
- 6
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC / Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| UCLA / Jonsson Comprehensive Cancer Center | Los Angeles | California | 90095 | — |
| California Pacific Medical Center-Pacific Campus | San Francisco | California | 94115 | — |
| UCSF Medical Center-Mount Zion | San Francisco | California | 94115 | — |
| UCHealth University of Colorado Hospital | Aurora | Colorado | 80045 | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| Clackamas Radiation Oncology Center | Clackamas | Oregon | 97015 | — |
| Providence Milwaukie Hospital | Milwaukie | Oregon | 97222 | — |
| Providence Newberg Medical Center | Newberg | Oregon | 97132 | — |
| Providence Willamette Falls Medical Center | Oregon City | Oregon | 97045 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Providence Saint Vincent Medical Center | Portland | Oregon | 97225 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| PeaceHealth Southwest Medical Center | Vancouver | Washington | 98664 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01902173, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 13, 2025 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01902173 live on ClinicalTrials.gov.